Risk and Prognosis of Campylobacteriosis in Relation to Polymorphisms of Host Inflammatory Cytokine Genes

Scandinavian Journal of Immunology

Volumn 75, Issue 4, 2012, Pages 449-454

  Nielsen, H ^a   Steffensen, R ^a   Ejlertsen, T ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18;

ADULT; ARTICLE; CAMPYLOBACTER ENTERITIS; FECES ANALYSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; INFECTION RISK; INTRON; IRRITABLE COLON; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REACTIVE ARTHRITIS; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM;

CAMPYLOBACTER COLI; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CYTOKINES; GASTROENTERITIS; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS;

EID: 84858590690     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02678.x     Document Type: Article

References (25)

1. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988;157:472-9.
2. Robinson DA. Infective dose of Campylobacter jejuni in milk. BMJ 1981;282:1584.
3. Teunis P, Brandhof WVD, Nauta M, Wagenaar J, Kerkhof HVD, Pelt WV. A reconsideration of the Campylobacter dose-response relation. Epidemiol Infect 2005;133:583-92.
4. Janssen R, Krogfelt KA, Cawthraw SA, Pelt WV, Wagenaar JA, Owen RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev 2008;21:505-18.
5. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 2009;137:495-501.
6. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006;43:898-901.
7. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-82.
8. Gwee KA, Graham JC, McKendrick MWM et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996;347:150-3.
9. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662-71.
10. Marshall JK, Thabane M, Garg AX, Clark W, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010;59:605-11.
11. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001;184:606-9.
12. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and its post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
13. Hannu T, Mattila L, Rautelin H et al. Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology 2002;41:312-8.
14. Johnsen K, Ostensen M, Melbye AC, Melby K. HLA-B27-negative arthritis related to Campylobacter jejuni enteritis in three children and two adults. Acta Med Scand 1983;214:165-8.
15. Doorduyn Y, Pelt WV, Siezen CLE et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008;136:1225-34.
16. Schiellerup P, Krogfelt KA, Locht H. A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27. J Rheumatol 2008;35:480-7.
17. Jiang ZD, Okhuysen PC, Guo DC et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003;188:506-11.
18. Sakai K, Kita M, Sawai N et al. Levels of interleukin-18 are markedly increased in Helicobacter pylori-infected gastric mucosa among patients with specific IL18 genotypes. J Infect Dis 2008;197:1752-61.
19. Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther 2007;26:953-61.
20. Nielsen H, Persson S, Olsen KEP, Ejlertsen T, Kristensen B, Schønheyder HC. Bacteraemia with Campylobacter jejuni: no association with the virulence genes iam, cdtB, capA or virB. Eur J Clin Microbiol Infect Dis 2010;29:357-8.
21. Daser A, Mitchison H, Mitchison A, Müller B. Non-classical-MHC genetics of immunological disease in man and mouse. The key role of pro-inflammatory cytokine genes. Cytokine 1996;8:593-7.
22. Geleijns K, Jacobs BC, Rijs WV, TioGillen AP, Laman JD, Doorn PAV. Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillan-Barré patients. J Neuroimmunol 2004;150:132-8.
23. Kretowski A, Mironczuk K, Karpinska A et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 2002;51:3347-9.
24. Sivalingam SP, Yoon KH, Koh DR, Fong KY. Single-nucleotide polymorphisms of the interleukin-18 gene promoter region in rheumatoid arthritis patients: protective effect of AA genotype. Tissue Antigens 2003;62:498-504.
25. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146-52.